---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-085566"
form_type: "8-K"
ticker: "SPRO"
cik: "0001701108"
company_name: "Spero Therapeutics, Inc."
filed_at: "2023-03-30T23:59:59+00:00"
generated_at: "2026-06-17T09:21:13.373931+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Spero Therapeutics reports Q4 net income of $26.8M; GSK deal provides $66M upfront

## Summary
- Q4 2022 net income $26.8M ($0.55 EPS) vs net loss $29.2M in Q4 2021; full-year net loss $46.4M ($1.23 loss per share).
- Total revenue Q4 2022 $47.4M (up from $2.7M) driven by $46.1M collaboration revenue from GSK and Pfizer deals.
- Cash and equivalents $109.1M as of Dec 31, 2022; company expects runway beyond 2024.
- Initiated Phase 2 trial of SPR720 in NTM-PD; top-line data expected in first half of 2024.
- GSK license for tebipenem HBr: $66M upfront, $9M equity investment, up to $525M milestones plus tiered royalties.

## SEC filing metadata
- accession: 0001193125-23-085566
- form_type: 8-K
- ticker: SPRO
- cik: 0001701108
- company_name: Spero Therapeutics, Inc.
- filed_at: 2023-03-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701108/000119312523085566/0001193125-23-085566-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701108/000119312523085566/d438825d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-085566
- JSON: https://secwatch.observer/filing/0001193125-23-085566.json
- Plain text: https://secwatch.observer/filing/0001193125-23-085566.txt

## Key facts
- Earnings Releases
  Spero Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2022.
  - Period: the fourth quarter and full year ended December 31, 2022
  - Result: reported results
  source text: On March 30, 2023, Spero Therapeutics, Inc. (the "Company") issued a press release announcing its results for the fourth quarter and full year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1701108/000119312523085566/0001193125-23-085566-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.